Daniel Markowitz
Stock Analyst at Evercore ISI Group
(4.71)
# 139
Out of 5,090 analysts
19
Total ratings
87.5%
Success rate
22.42%
Average return
Main Sectors:
Stocks Rated by Daniel Markowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Initiates: In-Line | $68 | $65.49 | +3.83% | 1 | Nov 25, 2025 | |
| NTRA Natera | Maintains: Outperform | $190 → $250 | $244.55 | +2.23% | 2 | Nov 7, 2025 | |
| GH Guardant Health | Maintains: Outperform | $68 → $90 | $102.02 | -11.78% | 2 | Oct 30, 2025 | |
| RMBS Rambus | Maintains: Outperform | $114 → $126 | $101.60 | +24.02% | 2 | Oct 28, 2025 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $350 → $390 | $280.23 | +39.17% | 3 | Oct 23, 2025 | |
| TECH Bio-Techne | Maintains: Outperform | $60 → $72 | $61.68 | +16.73% | 2 | Oct 7, 2025 | |
| RGEN Repligen | Maintains: Outperform | $155 → $175 | $164.98 | +6.07% | 4 | Oct 7, 2025 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $150 → $125 | $136.81 | -8.63% | 2 | Oct 7, 2025 | |
| TMDX TransMedics Group | Initiates: Outperform | $155 | $136.51 | +13.54% | 1 | Sep 16, 2025 |
DexCom
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $65.49
Upside: +3.83%
Natera
Nov 7, 2025
Maintains: Outperform
Price Target: $190 → $250
Current: $244.55
Upside: +2.23%
Guardant Health
Oct 30, 2025
Maintains: Outperform
Price Target: $68 → $90
Current: $102.02
Upside: -11.78%
Rambus
Oct 28, 2025
Maintains: Outperform
Price Target: $114 → $126
Current: $101.60
Upside: +24.02%
West Pharmaceutical Services
Oct 23, 2025
Maintains: Outperform
Price Target: $350 → $390
Current: $280.23
Upside: +39.17%
Bio-Techne
Oct 7, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $61.68
Upside: +16.73%
Repligen
Oct 7, 2025
Maintains: Outperform
Price Target: $155 → $175
Current: $164.98
Upside: +6.07%
Inspire Medical Systems
Oct 7, 2025
Maintains: Outperform
Price Target: $150 → $125
Current: $136.81
Upside: -8.63%
TransMedics Group
Sep 16, 2025
Initiates: Outperform
Price Target: $155
Current: $136.51
Upside: +13.54%